当前位置:
USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
时间:2024-06-26 17:23:22 阅读(143)
USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg.
According to the company’s press statement, the approval has been granted to market a generic equivalent of Qtern Tablets, 5 mg/5 mg and 10 mg/5 mg of AstraZeneca AB. This product will be manufactured at Lupin’s Pithampur facility in India.
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT November 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Zomato, Indiabulls Housing Finance, IDBI Bank among 123 stocks that hit 52-week highs; 8 touch 52-week lows
- Axis Bank, Wipro, Tech Mahindra, Godrej Consumer Products, LTIMindtree stocks in focus
- Auto ancillary stocks in top gear- What’s driving the rally-
- Bank Nifty failing to break through 42,000; inflation, Adani saga, FIIs weigh heavy on index
- Exploring Vijay Sethupathi’s staggering net worth, luxurious Chennai mansion, and exquisite car collection
- ZEEL, HDFC Bank, Axis Bank, Jindal Steel, Sanofi India, Titan stocks in focus
- Equity indices gain ahead of US inflation data
- Auto PLI allocation may remain unspent this fiscal; most firms yet to meet eligibility norms
- ATF purchases by Indian carriers for overseas flights exempt from 11% excise duty- Finance Ministry